Skip to main content

Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers-results from the DELCODE study.

Alzheimer's research & therapy

Authors: Lena Sannemann, Ann-Katrin Schild, Slawek Altenstein, Claudia Bartels, Frederic Brosseron, Katharina Buerger, Nicoleta Carmen Cosma, Klaus Fliessbach, Silka Dawn Freiesleben, Wenzel Glanz, Michael T Heneka, Daniel Janowitz, Ingo Kilimann, Xenia Kobeleva, Christoph Laske, Coraline D Metzger, Matthias H J Munk, Robert Perneczky, Oliver Peters, Alexandra Polcher, Josef Priller, Boris Rauchmann, Christina Rösch, Janna Rudolph, Anja Schneider, Annika Spottke, Eike Jakob Spruth, Stefan Teipel, Ruth Vukovich, Michael Wagner, Jens Wiltfang, Steffen Wolfsgruber, Emrah Duezel, Frank Jessen

BACKGROUND: Early identification of individuals at risk of dementia is mandatory to implement prevention strategies and design clinical trials that target early disease stages. Subjective cognitive decline (SCD) and neuropsychiatric symptoms (NPS) have been proposed as potential markers for early manifestation of Alzheimer's disease (AD). We aimed to investigate the frequency of NPS in SCD, in other at-risk groups, in healthy controls (CO), and in AD patients, and to test the association of NPS with AD biomarkers, with a particular focus on cognitively unimpaired participants with or without SCD-related worries.

METHODS: We analyzed data of n = 687 participants from the German DZNE Longitudinal Cognitive Impairment and Dementia (DELCODE) study, including the diagnostic groups SCD (n = 242), mild cognitive impairment (MCI, n = 115), AD (n = 77), CO (n = 209), and first-degree relatives of AD patients (REL, n = 44). The Neuropsychiatric Inventory Questionnaire (NPI-Q), Geriatric Depression Scale (GDS-15), and Geriatric Anxiety Inventory (GAI-SF) were used to assess NPS. We examined differences of NPS frequency between diagnostic groups. Logistic regression analyses were carried out to further investigate the relationship between NPS and cerebrospinal fluid (CSF) AD biomarkers, focusing on a subsample of cognitively unimpaired participants (SCD, REL, and CO), who were further differentiated based on reported worries.

RESULTS: The numbers of reported NPS, depression scores, and anxiety scores were significantly higher in subjects with SCD compared to CO. The quantity of reported NPS in subjects with SCD was lower compared to the MCI and AD group. In cognitively unimpaired subjects with worries, low Aß42 was associated with higher rates of reporting two or more NPS (OR 0.998, 95% CI 0.996-1.000, p < .05).

CONCLUSION: These findings give insight into the prevalence of NPS in different diagnostic groups, including SCD and healthy controls. NPS based on informant report seem to be associated with underlying AD pathology in cognitively unimpaired participants who worry about cognitive decline.

TRIAL REGISTRATION: German Clinical Trials Register DRKS00007966 . Registered 4 May 2015.

PMID: 33066827

Participating cluster members